|
Title
|
|
|
|
Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| In many settings, serotype changes as a result of infant 13-valent pneumococcal conjugate vaccine (PCV13) programs are likely to continue after the introduction of adult PCV13 programs. We applied a multi-cohort model to explore how potential serotype changes may impact on the cost-effectiveness of PCV13 use in Australian adults aged over 65 years. We found assumptions around continued herd protection from infant PCV13 programs to be critical when assessing the cost-effectiveness of adult PCV13 vaccination in Australia. Future cost-effectiveness analyses of adult PCV13 programs need to carefully consider how to predict these future changes in serotypes, with Australian data suggesting that the changes post-PCV13 use in infants may be different than post-PCV7. (C) 2018 Elsevier Ltd. All rights reserved. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Vaccine / International Society for Vaccines. - Amsterdam
|
|
|
Publication
|
|
|
|
Amsterdam
:
2018
|
|
|
ISSN
|
|
|
|
0264-410X
|
|
|
DOI
|
|
|
|
10.1016/J.VACCINE.2018.03.006
|
|
|
Volume/pages
|
|
|
|
36
:16
(2018)
, p. 2057-2060
|
|
|
ISI
|
|
|
|
000430525400001
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|